Reported Earnings • 4h
Second quarter 2026 earnings released: EPS: NT$1.05 (vs NT$1.06 in 2Q 2025) Second quarter 2026 results: EPS: NT$1.05 (down from NT$1.06 in 2Q 2025). Revenue: NT$227.3m (up 17% from 2Q 2025). Net income: NT$38.1m (down 1.3% from 2Q 2025). Profit margin: 17% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years. Upcoming Dividend • Jun 28
Upcoming dividend of NT$3.00 per share Eligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%). Declared Dividend • Jun 13
Dividend of NT$3.00 announced Shareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 15
First quarter 2026 earnings released First quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025). Reported Earnings • Mar 14
Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024) Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years. Duyuru • Mar 04
Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026 Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026. Location: 1 floor no,101, kung yeh rd., sihu township, changhua county Taiwan Board Change • Feb 25
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Qinglong Xie was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 15
Third quarter 2025 earnings released: EPS: NT$1.00 (vs NT$1.54 in 3Q 2024) Third quarter 2025 results: EPS: NT$1.00 (down from NT$1.54 in 3Q 2024). Revenue: NT$195.7m (down 1.4% from 3Q 2024). Net income: NT$30.8m (down 28% from 3Q 2024). Profit margin: 16% (down from 22% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Sep 16
Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.67 in 2Q 2024) Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.67 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue. Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.66 in 2Q 2024) Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.66 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue. New Risk • Jul 08
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$2.01b market cap, or US$69.1m). Upcoming Dividend • Jul 08
Upcoming dividend of NT$3.13 per share Eligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%). Reported Earnings • May 16
First quarter 2025 earnings released: EPS: NT$1.17 (vs NT$1.41 in 1Q 2024) First quarter 2025 results: EPS: NT$1.17 (down from NT$1.41 in 1Q 2024). Revenue: NT$174.7m (down 2.9% from 1Q 2024). Net income: NT$32.2m (down 9.7% from 1Q 2024). Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by lower revenue. New Risk • Apr 12
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.45b market cap, or US$75.8m). Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to NT$78.50, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 17x in the Personal Products industry in Taiwan. Total loss to shareholders of 64% over the past year. Reported Earnings • Apr 02
Full year 2024 earnings released: EPS: NT$6.02 (vs NT$5.90 in FY 2023) Full year 2024 results: EPS: NT$6.02 (up from NT$5.90 in FY 2023). Revenue: NT$748.4m (up 20% from FY 2023). Net income: NT$155.7m (up 5.1% from FY 2023). Profit margin: 21% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses. Duyuru • Mar 08
Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025 Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,101, kung yeh, sihu township, changhua county Taiwan New Risk • Dec 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$77.0m). New Risk • Nov 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$76.9m). Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to NT$95.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 38% over the past year. Buy Or Sell Opportunity • Oct 11
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 35% to NT$105. The fair value is estimated to be NT$143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 68% over the last year. Earnings per share has grown by 80%. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to NT$118, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 61% over the past year. New Risk • Sep 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.10b (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$3.10b market cap, or US$98.3m). New Risk • Sep 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.6% average weekly change). New Risk • Aug 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (15% increase in shares outstanding). New Risk • Jul 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.4m). New Risk • Apr 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.0% average weekly change). New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.63b market cap, or US$83.9m). New Risk • Jul 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.28b market cap, or US$72.8m).